一致Ｂ：2021年第一季度报告全文（英文版）.PDF

1China NationalAccord Medicines Corporation Ltd.First Quarterly Report 2021April 20212Section I. Important NotesBoard of Directors and the Supervisory Committee of China National AccordMedicines Corporation Ltd.(hereinafter referred to as the Company) and itsdirectors, supervisors and senior executives should guarantee the reality,accuracy and completion of the quarterly report, there are no any fictitiousstatements, misleading statements or important omissions carried in this report,and shall take legal responsibilities, individual and/or joint.All Directors are attended the Board Meeting for Quarterly Report deliberation.Lin Zhaoxiong person in charge of the Company, Gu Guolin, person in chargerof accounting works and Wang Ying, person in charger of accounting organ(accounting officer) hereby confirm that the Financial Report of this QuarterlyReport is authentic, accurate and complete.3Section II. Company profileI. Main accounting data and financial indexesWhether it has retroactive adjustment or re-statement on previous accounting dataYesNoCurrent PeriodSame period of last yearChanges of this period oversame period of last yearOperating income (RMB)16,049,966,325.7512,824,196,278.6625.15%Net profit attributable to shareholders ofthe listed Company (RMB)328,800,560.24248,800,655.8832.15%Net profit attributable to shareholders ofthe listed company after deductingnon-recurring gains and losses (RMB)321,593,612.98241,724,850.9533.04%Net cash flows from operating activities(RMB)-306,748,999.24-688,273,848.6355.43%Basic earnings per share (RMB/Share)0.770.5832.76%Diluted earnings per share (RMB/Share)0.770.5832.76%Weighted average ROE2.33%1.92%0.41 percentage point upAt the end of the reportingperiodAt the end of last yearChanges of this period-endover same period-end of lastyearTotal assets (RMB)43,020,753,415.9239,594,533,471.658.65%Net assets attributable to shareholder oflisted company (RMB)14,277,162,387.0413,948,322,652.332.36%Items of non-recurring gains and lossesApplicable Not applicableIn RMBItemAmount from year-begin toperiod-endNoteGains/losses from the disposal of non-current asset (including thewrite-off that accrued for impairment of assets)216,388.08The gains of disposal of theright-of-useassetsfromstorelease surrender and the loss fromfixed assets scrappingGovernmental subsidy reckoned into current gains/losses (notincluding the subsidy enjoyed in quota or ration according tonational standards, which are closely relevant to enterprisesbusiness)9,265,003.74Various special subsidies and taxrebates received in the Period4Switch back of provision for depreciation of account receivableand contract assets that are individually tested for impairment78,530.15Other non-operating income and expenditure except for theaforementioned items5,180,996.84The non-operating income arisingfrom written off the money notrequired to be paidOthergains/lossessatisfyadefinitionofextraordinarygains/losses609,647.62Less: Impact on income tax3,348,453.94Impact on minority shareholdersequity (post-tax)4,795,165.23Total7,206,947.26-Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for CompaniesOffering Their Securities to the Public - Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according tothe lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering TheirSecurities to the Public - Extraordinary Profit/loss, explain reasonsApplicable Not applicableIn reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists ofextraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities tothe Public - Extraordinary Profit/lossII. Total number of shareholders at the end of this report period and top ten shareholders1. Total number of common shareholders at the end of this report period and top ten common shareholdersIn sharesTotal common shareholders at theend of report period42,431Total preference shareholders withvoting rights recovered at end ofreporting period (if applicable)0Top ten shareholdersShareholdersnameNature ofshareholderProportion ofshares heldAmount of sharesheldAmount ofrestricted sharesheldNumber of share pledged/frozenState of shareAmountSinopharm GroupCo., Ltd.State-owned legalperson56.06%239,999,9915,505,770Hong KongSecuritiesClearingCompany LtdForeignCorporation3.55%15,215,743FIRST SENTIERINVESTORSGLOBALUMBRELLAForeignCorporation2.68%11,469,6445FUND PLC -FSSACHINAGROWTHFUNDChina NationalPharmaceuticalForeign TradeCorp.State-owned legalperson1.24%5,323,043National SocialSecurity Fund-portfolio 413Domestic nonstate-ownedCorporation0.97%4,161,032Central HuijinInvestment Ltd.State-owned legalperson0.89%3,804,400BBH BOS S/AFIDELITY FD -CHINAFOCUSFDForeignCorporation0.78%3,358,761CPIC Fund-China PacificLife InsuranceCo., Lt. -participatinginsurance -CPICfund PICC StockRelative Income(guaranteedbonus)singleassetmanagement planDomestic nonstate-ownedCorporation0.66%2,822,801FidelityInvestmentManagement(Hong Kong)Limited - ClientsfundForeignCorporation0.54%2,308,237ChinaConstructionBank Co., Ltd. -China EuropeValue DiscoveryEquity FundDomestic nonstate-ownedCorporation0.45%1,921,921Top ten shareholders with unrestricted shares held6Shareholders nameAmount of unrestricted shares heldType of sharesTypeAmountSinopharm Group Co., Ltd.234,494,221RMBordinaryshares234,494,221Hong Kong Securities ClearingCompany Ltd15,215,743RMBordinaryshares15,215,743FIRST SENTIER INVESTORSGLOBAL UMBRELLAFUND PLC- FSSACHINAGROWTH FUND11,469,644Domesticlistedforeign shares11,469,644China National PharmaceuticalForeign Trade Corp.5,323,043RMBordinaryshares5,323,043National Social Security Fund-portfolio 4134,161,032RMBordinaryshares4,161,032Central Huijin Investment Ltd.3,804,400RMBordinaryshares3,804,400BBH BOS S/AFIDELITY FD -CHINAFOCUS FD3,358,761Domesticlistedforeign shares3,358,761CPIC Fund- China Pacific LifeInsurance Co., Lt. - participatinginsurance -CPIC fund PICC StockRelative Income (guaranteedbonus)single asset management plan2,822,801RMBordinaryshares2,822,801Fidelity Investment Management(Hong Kong) Limited - Clients fund2,308,237RMBordinaryshares2,308,237China Construction Bank Co., Ltd. -China Europe Value DiscoveryEquity Fund1,921,921RMBordinaryshares1,921,921ExplanationonassociatedrelationshipamongtheaforesaidshareholdersSinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporationhave the same actual controller, which is China National Pharmaceutical Group Corporation.It is unknown that there exists no associated relationship or belongs to the consistent actionistamong the other tradable shareholders regulated by the Management Measure of InformationDisclosure on Change of Shareholding for Listed Companies.Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreementdealing in reporting period Yes NoThe top ten common shareholders or top ten common shareholders with un-restrict shares held of the Company have no buy-backagreement dealing in reporting period.72. Total shareholders with preferred stock held at Period-end and shares held by top ten shareholders withpreferred stock heldApplicable Not applicable8Section III. Significant EventsI. Particulars about material changes in items of main accounting statement and financialindex and explanations of reasonsApplicable Not applicable1.Receivable financing: a decrease of 973.0057 million Yuan compared with the beginning of the period, with a growth rate of-69.25%, mainly because the bank acceptance bill discount in the Period increased;2. Short-term borrowings: an increase of 2335.6654 million Yuan compared with the beginning of the period, with a growth rate of144.88%, mainly because the supply chain financing increased in the Period;3. Employee benefits payable: a decrease of 115.9978 million Yuan compared with the beginning of the period, with a growth rate of-32.47%, mainly because the salaries and bonus accrued in the previous year are paid in the Period;4. Other payables: an increase of 499.6124 million Yuan compared with the beginning of the period, with a growth rate of 31.24%,mainly due to the equity consideration payable arising from acquisition of Yunnan Guoda Disheng Drugstore Chain Co., Ltd andYunnan Guoda Disheng Pharmacy Co., ltd by subsidiary of the company -Sinopharm Holding Guoda Drugstore Co., Ltd. (hereinafterreferred to as Guoda Drugstore), and the factoring return of unrecoverable account receivable increased in the Period;5. Finance costs: an increase of 21.6634 million Yuan on a year-on-year basis, with a growth rate of 74.67%, mainly because paying alarge amount of equity acquisition consideration in 2020, resulting in a reduction in bank deposit, and the interest from bank depositdeclined correspondingly, and the interest expenses on supply chain financing increased on a y-o-y basis;6. Investment income: an increase of 48.6294 million Yuan on a year-on-year basis, with a growth rate of 113.95%, mainly becausethe investment income from associated enterprise increased from a year earlier;7. Impairment losses: an increase of 1.8901 million Yuan on a year-on-year basis, with a growth rate of 118.24%, mainly becauseprovision for falling price of inventories increased on a y-o-y basis;8. Gain on disposal of assets: an increase of 0.5332 million Yuan on a year-on-year basis, with a growth rate of 204.07%, mainly dueto the gains of disposal of the right-of-use assets from retail store lease surrender;9. Non-operating income: an increase of 4.5591 million Yuan on a year-on-year basis, with a growth rate of 251.64%, mainly becausewritten off the money not required to be paid in the Period;10. Non-operating expenses: a decrease of 1.1396 million Yuan on a year-on-year basis, with a growth rate of -66.63%, mainlybecause the amercement outlay declined in the Period;11. Net profit: an increase of 94.4755 million Yuan on a year-on-year basis, with a growth rate of 32.02%, mainly because operationin the Period has a growth performance, soaring operation income makes the gross profit increased and the investment income fromassociated enterprise increased from a year earlier;12. Profit or loss from continuing operations: an increase of 94.4755 million Yuan on a year-on-year basis, with a growth rate of32.02%, mainly because operation in the Period has a growth performance, soaring operation income makes the gross profitincreased and the investment income from associated enterprise increased from a year earlier;13. Net profit attributable to owners of the parent company: an increase of 79.9999 million Yuan on a year-on-year basis, with agrowth rate of 32.15 %, mainly because operation in the Period has a growth performance, soaring operation income makes the grossprofit increased and the investment income from associated enterprise increased from a year earlier;14. Net profit attributable to non-controlling interests: an increase of 14.4755 million Yuan on a year-on-year basis, with a growthrate of 31.27%, mainly because the subsidiary Guoda Drugstores net profit attributable to the owners of the parent companyincreased year-on-year, correspondingly theminority shareholders gains/losses attributable to the groups strategic investorWalgreens BootsAlliance (Hong Kong) Investments Limited (hereinafter referred to as WBA) increased ;915. Other comprehensive income, net of tax: an increase of 84,503.76Yuan on a year-on-year basis, with a growth rate of 100.00%,mainly because other comprehensive income of associates changed during the current period;16. Other comprehensive income attributable to shareholders of owners of the parent, net of tax: an increase of 84,503.76 Yuan on ayear-on-year basis, with a growth rate of 100.00%, mainly because other comprehensive income of associates changed during thecurrent period;17. Other comprehensive income that may be reclassified to profit or loss: an increase of 84,503.76 Yuan on a year-on-year basis,with a growth rate of 100.00%, mainly due to the other comprehensive income available for transfer to profit/loss arising fromassociates in the Period;18. Total comprehensive income: an increase of 94.56 million Yuan on a year-on-year basis, with a growth rate of 32.04%, mainlydue to the relatively good operating growth in the current period, gross profit increased for the soaring operation income, and theinvestment income from associates increased on a y-o-y basis;19. Total comprehensive income attributable to owners of the parent: an increase of 80.0844 million Yuan on a year-on-year basis,with a growth rate of 32.19%, mainly due to the relatively good operating growth in the current period, gross profit increased for thesoaring operation income, and the investment income from associates increased on a y-o-y basis;20. Total comprehensive income attributable to non-controlling interests: an increase of 14.4755 million Yuan on a year-on-year basis,with a growth rate of 31.27%, mainly because the net profit attributable to owners of parent company from subsidiary GuodaDrugstore has an increased from a year earlier, and correspondingly the minority shareholders gains/losses attributable to the groupsstrategic investor WBA increased ;21. Basic earnings per share: an increase of 0.19 Yuan/share on a year-on-year basis, with a growth rate of 32.76%, mainly due to therelatively good operating growth in the current period, gross profit increased for the soaring operation income, and the investmentincome from associates increased on a y-o-y basis, therefore, the net profit attributable to shareholders of listed company increased32.15% from a year earlier, basic EPS growth correspondingly with 32.76% up;22. Diluted earnings per share: an increase of 0.19 Yuan/share on a year-on-year basis, with a growth rate of 32.76%, mainly due tothe relatively good operating growth in the current period, gross profit increased for the soaring operation income, and the investmentincome from associates increased on a y-o-y basis, therefore, the net profit attributable to shareholders of listed company increased32.15% from a year earlier, diluted EPS growth correspondingly with 32.76% up;23. Receipts of taxes and surcharges refunds: an increase of 4.8427 million Yuan on a year-on-year basis, with a growth rate of624.66%, mainly due to the receipt of overpaid corporate income tax rebates in previous years;24. Other cash receipts relating to operating activities: a decrease of 223.6696 million Yuan on a year-on-year basis, with a growthrate of -51.61%, mainly due to the year-on-year decrease in special reserve funds received in this period;25. Net cash flows from operating activities: an increase of 381.5248 million Yuan on a year-on-year basis, with a growth rate of55.43%, mainly due to the increase in operating income, the